SCHEMBL6352897

SCHEMBL6352897

CN1CCCN(c2cncc(-c3cccnc3)c2)CC1

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.49
CYP3A4 P08684 4/20 0.49
CYP2D6 P10635 4/20 0.49
ALDH1A1 P00352 3/20 0.49
CLK4 Q9HAZ1 3/20 0.49
LMNA P02545 2/20 0.49
ALOX15 P16050 2/20 0.49
MEN1 O00255 1/20 0.49
MAPK1 P28482 1/20 0.49
KMT2A Q03164 1/20 0.49
TSHR P16473 2/20 0.49
HSD17B10 Q99714 2/20 0.49
HTR6 P50406 1/20 0.47
RPS6KA3 P51812 1/20 0.46
CYP11B2 P19099 1/20 0.46
CHEK1 O14757 1/20 0.45
CHRNB2 P17787 1/20 0.44
CHRNA4 P43681 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6352719 0.94 CYP1A2 (0.53) CYP1A2CYP3A4CYP2D6ALDH1A1CLK4
SCHEMBL6357589 0.89 CHEK1 (0.53) CYP11B2CHEK1
SCHEMBL6354314 0.86 MELK (0.52) CYP11B2CHEK1
SCHEMBL5655570 0.84 CHRNB2 (0.61) CYP1A2CYP3A4CYP2D6ALDH1A1TSHR
SCHEMBL3453906 0.83 CHEK1 (0.58) CYP11B2CHEK1
SCHEMBL6358630 0.82 HRH4 (0.52) ALDH1A1LMNACHRNB2CHRNA4
SCHEMBL6352765 0.81 CHRNB2 (0.61) CYP1A2CYP3A4CYP2D6ALDH1A1CLK4
SCHEMBL6350619 0.81 HTR1A (0.45) HTR6CYP11B2
SCHEMBL6353048 0.80 HRH4 (0.52) HTR6CYP11B2CHEK1
SCHEMBL6350323 0.80 MELK (0.57) CYP1A2RPS6KA3CYP11B2CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825189-B1 TREATING WITHDRAWAL SYMPTOMS CAUSED BY SMOKING CESSATION NEUROSEARCH A/S (DK) 2004-11-30 US claimed
EP-1027336-B1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH AS (DK) 2004-10-06 EP claimed
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; NEUROSEARCH A/S 2004-04-15 US claimed
US-20030032801-A1 Chemosensitizing agents against chloroquine resistant plasmodium falciparum and methods of making and using thereof U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND 2003-02-13 US claimed
US-6897219-B2 Heteroaryl diazacycloalkanes, their preparation and use NEUROSEARCH A/S (DK) 2005-05-24 US disclosed
US-6825189-B1 TREATING WITHDRAWAL SYMPTOMS CAUSED BY SMOKING CESSATION NEUROSEARCH A/S (DK) 2004-11-30 US disclosed
EP-1027336-B1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH AS (DK) 2004-10-06 EP disclosed
US-6800618-B2 PHENOTHIAZINE OR IMINODIBENZYL DERIVATIVES AS ANTIMALARIAL AGENTS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY 2004-10-05 US disclosed
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; NEUROSEARCH A/S 2004-04-15 US disclosed
CN-1131211-C Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors NEUROSEARCH AS (DK) 2003-12-17 CN disclosed
US-20030032801-A1 Chemosensitizing agents against chloroquine resistant plasmodium falciparum and methods of making and using thereof U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND 2003-02-13 US disclosed
CN-1277604-A Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors NEUROSEARCH AS (DK) 2000-12-20 CN disclosed
EP-1027336-A1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 2000-08-16 EP disclosed
WO-1999021834-A1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030032801-A1 Chemosensitizing agents against chloroquine resistant plasmodium falciparum and methods of making and using thereof ABCC1, SLC11A2, G6PD CYP1A2 374/4885CYP3A4 350/4885CYP2D6 31/4885
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; OGFR, CBR3, OGFRL1 CYP1A2 162/4885CYP3A4 346/4885CYP2D6 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.